Faeth Therapeutics
FTH
24 hedge funds and large institutions have $2.43M invested in Faeth Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
18% more capital invested
Capital invested by funds: $2.05M → $2.43M (+$375K)
4% more funds holding
Funds holding: 23 → 24 (+1)
0.13% less ownership
Funds ownership: 0.59% → 0.46% (-0.13%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$58.2K |
| 2 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$17K |
| 3 |
Morgan Stanley
New York
|
+$10.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$155 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$121 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$553K |
| 2 |
DFO
Duquesne Family Office
New York
|
-$69K |
| 3 |
Millennium Management
New York
|
-$4.93K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.67K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$414 | -24 | -89% |
|
FTH Hedge Fund Activity: Q1 2024 in Review
24 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2024, worth a combined $2.43M — up 18% from $2.05M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new FTH positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $58.2K. The largest seller was Newtyn Management, cutting an estimated $553K.
- 24 institutional investors held Faeth Therapeutics (FTH) as of Q1 2024, up from 23 in Q4 2023.
- Funds reported $2.43M of Faeth Therapeutics stock for Q1 2024, up 18% quarter-over-quarter.
- 2 funds opened new Faeth Therapeutics positions in Q1 2024 and 1 closed out, a net change of +1 holder.
- The largest Faeth Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $58.2K added.
- The largest Faeth Therapeutics seller in Q1 2024 was Newtyn Management, an estimated $553K sold.
Based on aggregated 13F filings for Q1 2024.